Evolus upgraded to Overweight from Equal Weight at Barclays

Barclays upgraded Evolus to Overweight from Equal Weight with a price target of $16, up from $10. The analyst sees the generics and biosimilars outlook as the “healthiest in years,” with easing generic deflation and rising loss of exclusivity opportunities. The firm upgraded the specialty pharmaceuticals industry to Specialty Pharmaceuticals along with Evolus. It cites the company’s execution and portfolio for the upgrade.